Results 61 to 70 of about 2,156,166 (288)

Fixed Dosing of Monoclonal Antibodies in Oncology

The Oncologist, 2017
In the field of oncology, most drugs are administered in a body–size‐based dosing schedule instead of a fixed dose for all patients. This article presents the advantages of fixed dosing of monoclonal antibodies, arguing in favor of fixed dosing schemes ...
J. Hendrikx, J. Haanen, E. Voest, J. Schellens, A. Huitema, J. Beijnen   +5 more
semanticscholar   +1 more source

Development of therapeutic antibodies for the treatment of diseases

Journal of Biomedical Sciences, 2020
It has been more than three decades since the first monoclonal antibody was approved by the United States Food and Drug Administration (US FDA) in 1986, and during this time, antibody engineering has dramatically evolved.
Ruei-Min Lu, Yu-Chyi Hwang, I. Liu, Chi-Chiu Lee, Han-zen Tsai, Hsin-Jung Li, Han‐Chung Wu   +6 more
semanticscholar   +1 more source

Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker

Molecular Oncology, EarlyView.
Urinary LGALS3BP is elevated in bladder cancer patients compared to healthy controls as detected by the 1959 antibody–based ELISA. The antibody shows enhanced reactivity to the high‐mannose glycosylated variant secreted by cancer cells treated with kifunensine (KIF).
Asia Pece, Giulio Lovato, Ilaria Cela, Arianna Mercatelli, Benedetta Ferro, Jussi Nikkola, Sara Pagotto, Tommaso Grottola, Vincenzo De Laurenzi, Rossella Cicchetti, Antonio Marchetti, Luigi Schips, Rossano Lattanzio, Stefano Iacobelli, Emily Capone, Peter Black, Mads Daugaard, Michele Marchioni, Gianluca Sala   +18 more
wiley   +1 more source

Special Issue: Monoclonal Antibodies

Antibodies, 2018
Monoclonal antibodies are utilized in clinical practice for the treatment of various diseases including cancer, autoimmunity, metabolic and infectious diseases [...]
Christian Klein
doaj   +1 more source

From rabbit antibody repertoires to rabbit monoclonal antibodies

Experimental &Molecular Medicine, 2017
In this review, we explain why and how rabbit monoclonal antibodies have become outstanding reagents for laboratory research and increasingly for diagnostic and therapeutic applications.
Justus Weber, Haiyong Peng, C. Rader
semanticscholar   +1 more source

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

Science, 2020
Protective neutralizing antibodies Antibodies produced by survivors of coronavirus disease 2019 (COVID-19) may be leveraged to develop therapies. A first step is identifying neutralizing antibodies, which confer strong protection against severe acute ...
T. Rogers, Fangzhu Zhao, Deli Huang, N. Beutler, Alison Burns, Wan-ting He, Oliver Limbo, C. Smith, G. Song, J. Woehl, Linlin Yang, R. Abbott, Sean Callaghan, Elijah Garcia, Jonathan Hurtado, M. Parren, Linghang Peng, S. Ramirez, James Ricketts, M. Ricciardi, Stephen A. Rawlings, N. Wu, M. Yuan, Davey M. Smith, D. Nemazee, J. Teijaro, J. Voss, I. Wilson, Raiees Andrabi, Bryan S. Briney, E. Landais, D. Sok, J. Jardine, D. Burton   +33 more
semanticscholar   +1 more source

CDK11 inhibition induces cytoplasmic p21WAF1 splice variant by p53 stabilisation and SF3B1 inactivation

Molecular Oncology, EarlyView.
CDK11 inhibition stabilises the tumour suppressor p53 and triggers the production of an alternative p21WAF1 splice variant p21L, through the inactivation of the spliceosomal protein SF3B1. Unlike the canonical p21WAF1 protein, p21L is localised in the cytoplasm and has reduced cell cycle‐blocking activity.
Radovan Krejcir, Lukasz Arcimowicz, Lucia Martinkova, Vaclav Hrabal, Filip Zavadil Kokas, Tomas Henek, Martina Kucerikova, Ondrej Bonczek, Pavlina Zatloukalova, Lenka Hernychova, Philip J. Coates, Borivoj Vojtesek, David P. Lane   +12 more
wiley   +1 more source

Advancements in the application of reporter gene cell lines in bioactivity evaluation of biological products

Bioresources and Bioprocessing
The assessment of biological product activity is a key aspect of quality control. Currently, in vitro assays serve as the primarily method employed by both companies and regulatory agencies to evaluate biological activity.
Kaijuan Yi, Can Wang, Huili Lu
doaj   +1 more source

Therapeutic Monoclonal Antibodies

The Keio Journal of Medicine, 2011
Over a hundred years has passed since the discovery of the "magic bullet" serum therapy by Kitasato and Behring, the first ever therapeutic use of antibodies. More than 80 years later, the investigation of immunoglobulin structure and function and the development of cell and molecular biology introduced the production of monoclonal antibodies (MoAbs ...
openaire   +3 more sources

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

Molecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia, Noelia Moares, Wenjie Yi‐He, Rosa Luna‐Espejo, Ricardo Fernandez‐Cisnal, Javier Ocaña‐Cuesta, Juan P. Muñoz‐Miranda, Antonio Gabucio, Cecilia M. Fernandez‐Ponce, Francisco Garcia‐Cozar   +9 more
wiley   +1 more source